Non-Small Cell Lung Cancer (NSCLC)

Treatment Options for Patients with EGFRm NSCLC

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Will Neo-Adjuvant Therapies Replace Surgery plus Adjuvant Treatment for Resectable NSCLC?

Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Patient Case: KRAS G12C Non–Small Cell Lung Cancer

Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Clinical Scenario: A PD-L1-Low Patient with NSCLC

Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Patient Profile: A 57-Year-Old Woman with NSCLC

Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Patient Case: A 76-Year-Old Woman with ROS1+ Metastatic NSCLC

Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Amivantamab plus Lazertinib in Atypical EGFR-mutated Advanced NSCLC: Results from CHRYSALIS-2

Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Osimertinib for EGFRm Stage III Unresectable NSCLC: The LAURA Trial

Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC: 5-Year Outcomes from the Phase III CROWN Study

Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in TKI-naïve ALK-rearranged Metastatic NSCLC

Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

Introduction of the Non–Small Cell Lung Cancer Face-Off

Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.

Joshua K. Sabari, MD;Roy S. Herbst, MD, PhD;Edward S. Kim, MD, MBA;Jyoti D. Patel, MD;Divya M. Gupta, MD;Laila A. Gharzai, MD;Rajat Thawani, MBBS;Faith Abodunrin, MD;Robert Cameron, MD, PhD

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Russ Conroy

Later-Line Treatment of Patients with Metastatic NSCLC

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Isabel Preeshagul, DO, MBS, with the Oncology Brothers presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Isabel Preeshagul, DO, MBS

Treating Patients with NSCLC and Actionable Mutations Following Progression

The Oncology Brothers and Isabel Preeshagul, DO, MBS, share clinical insights on later-line treatment practices for patients with metastatic non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Isabel Preeshagul, DO, MBS

Dual Checkpoint Inhibitors with Chemotherapy in Metastatic NSCLC

Isabel Preeshagul, DO, MBS, and the Oncology Brothers discuss the treatment of patients with NSCLC and actionable mutations following progression on first-line therapy.

Rahul Gosain, MD;Rohit Gosain, MD;Isabel Preeshagul, DO, MBS

Treating Newly Diagnosed Metastatic NSCLC with No Actionable Mutations in the First Line

Medical oncologists discuss the role of dual checkpoint inhibitors with chemotherapy in the treatment of patients with metastatic non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Isabel Preeshagul, DO, MBS

Telomere-Targeting Agent Demonstrates Tolerability in Advanced NSCLC

Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for newly diagnosed patients with metastatic non–small cell lung cancer (NSCLC) and no actionable mutations.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

Roman Fabbricatore

July 23rd 2024

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

Feedback from a Type C meeting signals the end of preparatory regulatory interactions for the phase 3 TACTI-004 trial’s design in metastatic NSCLC.

FDA Gives Positive Feedback on Phase 3 Eftilagimod Alfa NSCLC Trial Design

Russ Conroy

July 23rd 2024

Feedback from a Type C meeting signals the end of preparatory regulatory interactions for the phase 3 TACTI-004 trial’s design in metastatic NSCLC.

Preclinical data support the potential anti-tumor activity and tolerability of a novel FR⍺ topoisomerase I inhibitor in ovarian cancer and NSCLC.

FDA Clears New Drug Application for ZW191 in FR⍺+ Ovarian Cancer, NSCLC

Russ Conroy

July 22nd 2024

Preclinical data support the potential anti-tumor activity and tolerability of a novel FR⍺ topoisomerase I inhibitor in ovarian cancer and NSCLC.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

NSCLC Treatment: MET Exon 14 Skipping Mutations and RET Rearrangements

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS

Therapeutic Options for NSCLC with Rare Mutations

Balazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS

Treatment Approach for NSCLC with ALK Mutations

The Oncology Brothers and Balazs Halmos, MD, provide clinical insights on therapeutic options for patients with NSCLC with rare mutations, including ROS1, BRAF V600E, and NTRK.

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS

Approach to Treating Patients with NSCLC with Uncommon EGFR Mutations

Medical oncologists discuss therapeutic practices for patients with non–small cell lung cancer with ALK mutations.

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS

Treatment Algorithm for NSCLC with Common Sensitizing EGFR Mutations

A thoracic medical oncologist provides insights on the treatment of patients with non–small cell lung cancer with uncommon EGFR mutations.

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS